Stock Research for APHB


Featured Broker: Ally Invest

Get the due diligence for another stock.


APHB Stock Chart & Research Data

The APHB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the APHB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


APHB Due diligence Resources & Stock Charts

The APHB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View APHB Detailed Price Forecast - CNN Money CNN View APHB Detailed Summary - Google Finance
Yahoo View APHB Detailed Summary - Yahoo! Finance Zacks View APHB Stock Research & Analysis -

Stock Analysis

TradeIdeas View APHB Trends & Analysis - Trade-Ideas Barrons View APHB Major Holders - Barrons
NASDAQ View APHB Call Transcripts - NASDAQ Seeking View APHB Breaking News & Analysis - Seeking Alpha
Spotlight View APHB Annual Report - OTC Report View APHB OTC Short Report -
TradeKing View APHB Fundamentals - TradeKing Charts View APHB SEC Filings - Bar Chart
WSJ View Historical Prices for APHB - The WSJ Morningstar View Performance/Total Return for APHB - Morningstar
MarketWatch View the Analyst Estimates for APHB - MarketWatch CNBC View the Earnings History for APHB - CNBC
StockMarketWatch View the APHB Earnings - StockMarketWatch MacroAxis View APHB Buy or Sell Recommendations - MacroAxis
Bullish View the APHB Bullish Patterns - American Bulls Short Pains View APHB Short Pain Metrics -

Social Media Mentions

StockTwits View APHB Stock Mentions - StockTwits PennyStocks View APHB Stock Mentions - PennyStockTweets
Twitter View APHB Stock Mentions - Twitter Invest Hub View APHB Investment Forum News - Investor Hub
Yahoo View APHB Stock Mentions - Yahoo! Message Board Seeking Alpha View APHB Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for APHB - Insider Cow View Insider Transactions for APHB - Insider Cow
CNBC View APHB Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for APHB - OTC Markets
Yahoo View Insider Transactions for APHB - Yahoo! Finance NASDAQ View Institutional Holdings for APHB - NASDAQ

Stock Charts

FinViz View APHB Stock Insight & Charts - StockCharts View APHB Investment Charts -
BarChart View APHB Stock Overview & Charts - BarChart Trading View View APHB User Generated Charts - Trading View

Latest Financial News for APHB

4 Healthcare Stocks To Watch On Friday (1/4/19)
Posted on Friday January 04, 2019

CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday. Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share.

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge
Posted on Friday January 04, 2019

AmpliPhi Biosciences Corporation (“AmpliPhi”) (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and C3J Therapeutics, Inc. (“C3J”), a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials, today announced that the companies have entered into a definitive agreement under which a wholly owned subsidiary of AmpliPhi will merge with C3J in an all-stock transaction, subject to shareholder approval. The consummation of the merger transaction will result in a combined company that has a diverse clinical-stage pipeline, including a Phase 1/2-ready natural phage candidate targeting bacteremia, as well as a synthetic phage candidate targeting respiratory infections poised to enter Phase 1 development later this year.

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development
Posted on Tuesday December 18, 2018

AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced a 10-fold increase in yield from its manufacturing process, the result of a continuous and ongoing effort to enhance manufacturing efficiencies for AB-SA01, the company’s clinical stage lead drug product candidate. AB-SA01 is a targeted bacteriophage therapeutic in clinical development for the treatment of serious and life-threatening S. aureus infections, including those that do not respond to antibiotic therapy.

APHB: Phase 2 Trial of AB-SA01 in Bacteremia to Initiate 1H19…
Posted on Thursday November 29, 2018

On October 8, 2018, AmpliPhi Biosciences Corp. (APHB) announced the presentation of data on the company’s expanded access program for AB-SA01 at IDWeek 2018. The presentation “Adjunctive bacteriophage therapy for sever Staphylococcal sepsis” was given by Prof. Jonathan Iredell, Senior Staff Infectious Disease Physician at the Westmead Hospital in Sydney, Australia. Ten of those patients also had infective endocarditis, with five of them having prosthetic valve endocarditis.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.